<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151632</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS 030200</org_study_id>
    <secondary_id>PHRC/01-01</secondary_id>
    <secondary_id>CIC0203/011</secondary_id>
    <nct_id>NCT00151632</nct_id>
  </id_info>
  <brief_title>Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation</brief_title>
  <acronym>MMF-FK</acronym>
  <official_title>Evaluation of the Benefit/Risk Ratio of a Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil on the Prevention of Complications in Adult Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevention of graft rejection after liver transplantation benefits nowadays from a
      variety of newly developed immunosuppressive agents. This allows more flexible and
      individualized immunoprophylaxis and gives an opportunity to reduce the long-term side
      effects (hypertension, renal failure, diabetes, etc.) of immunosuppression. The purpose of
      this study is to evaluate, in liver transplanted patients, if low doses of tacrolimus, given
      in combination with mycophenolate mofetil, can result in a lower rate of long-term side
      effects without increasing the rate of graft rejection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tacrolimus and mycophenolate mofetil are currently approved immunosuppressive agents for the
      prevention of acute and chronic rejection in liver transplantation. Adverse effects of
      tacrolimus are dose-dependent and appear early after the onset of treatment. To prevent side
      effects, we propose to combine reduced doses of tacrolimus with another immunosuppressant,
      i.e. mycophenolate mofetil, administered at usual doses. This study evaluates the interest of
      this combination and, subsequently, the pharmacokinetics of mycophenolate mofetil in this
      therapeutic context. Patients undergoing liver transplantation will be randomized to
      tacrolimus at normal doses or to the combination of tacrolimus at half doses and
      mycophenolate mofetil. A corticotherapy will be associated in both groups. The safety will be
      evaluated on the number of graft rejections between day 1 after transplantation and week 48;
      the onset of complications (hypertension, renal failure, diabetes, etc.) will allow to
      evaluate the efficacy of both treatment schedules.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset of acute rejection (criterion evaluating the risk)</measure>
    <time_frame>between Day 1 and Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Onset of at least one complication (hypertension, renal failure, diabetes) requiring a specific treatment (criterion evaluating the benefit)</measure>
    <time_frame>between Week 9 and Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of hypertension, renal failure, diabetes, hypercholesterolemia, or of a serious adverse effect of mycophenolate mofetil</measure>
    <time_frame>between Day 1 and Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>MMF+FK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low doses of tacrolimus in association with mycophenolate mofetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Full recommended doses of tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.</description>
    <arm_group_label>MMF+FK</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CELLCEPT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.
In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12.</description>
    <arm_group_label>MMF+FK</arm_group_label>
    <arm_group_label>FK</arm_group_label>
    <other_name>FK</other_name>
    <other_name>PROGRAF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18 years of age

          -  Primary liver transplantation

          -  Immunosuppressive treatment associating tacrolimus and steroids at low doses (&lt; 20
             mg/d)

          -  Written informed consent

        Non-Inclusion Criteria:

          -  Pregnancy or ineffective contraception

          -  Immunosuppressive treatment

          -  Blood group incompatibility with the donor

          -  Autoimmune hepatitis

          -  Fulminant hepatitis

          -  Primary sclerosing cholangitis

          -  Combined transplantations

          -  Reduced liver

          -  Living donor

          -  Treated hypertension and/or diastolic pressure ≥ 90 mmHg and/or systolic pressure ≥
             140 mmHg,

          -  Acute or chronic renal failure(creatininemia ≥ 130 μmol/L) before transplantation

          -  Treated diabetes and/or fasting glycemia ≥ 7 mmol/L

          -  Treated hypercholesterolemia and/or cholesterolemia ≥ 7 mmol/L

          -  post-operative creatininemia ≥ 200 μmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Boudjema, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive - Hôpital de la Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgie Générale et Digestive - Hôpital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépaogastroentérologie - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Générale - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Chirurgie Viscérale - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hépato-biliaire - Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl TE, Fung JJ. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998 Nov 27;66(10):1395-8.</citation>
    <PMID>9846530</PMID>
  </reference>
  <reference>
    <citation>Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, Settmacher U, Radtke C, Neuhaus R, Neuhaus P. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc. 1999 Feb-Mar;31(1-2):1113-4.</citation>
    <PMID>10083497</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Acute graft rejection</keyword>
  <keyword>Treatment combination</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

